Clinical trial · Observational
A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting
HR POSITIVE, HER 2 NEGATIVE ADVANCED BREAST CANCER- TREATMENT PATTERNS IN POLAND - HABER STUDY
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is descriptive and aims to characterize the treatment patterns of advanced breast cancer in Poland in the real-world data setting. The main goals are to assess the current treatment patterns of hormone receptor-positive (HR+) Human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer and their changes in clinical practice and relate them to patients' demographics, disease characteristics, type of other therapies used in patients as well as disease progression and visceral crisis occurrence.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Number of Participants With HR+ HER2- Advanced Breast Cancer (ABC) Treatment Patterns
- timeFrame
- 01 September 2020 through 31 August 2021
Secondary outcomes (17)
- measure
- Number of Changes in Clinical Practice During One Year Observational Period in Relation to the Local Breast Cancer (BC) Treatment Guidelines
- timeFrame
- 01 September 2020 through 31 August 2021
- measure
- Correlation of Treatment Patterns With the Reference of the si.+-te Defined by Number of Enrolled Patients
- timeFrame
- 01 September 2020 through 31 August 2021
- measure
- Demographical Characteristics of Participants
- timeFrame
- 01 September 2020 through 31 August 2021
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients with histologically diagnosed advanced breast cancer (with locoregional recurrence not eligible for radical local treatment or with distant metastases) * Patient has a documented hormone (estrogen and/or progesterone) receptor expression and lack of HER2 receptor overexpression or lack of HER2 gene amplification (HR+/HER2- breast cancer subtype) * Patient had no prior treatment for advanced breast cancer * Patient has no symptomatic metastases to the central nervous system * There is no other malignancies in patient requiring active treatment * Patient is without co-occurring other malignancies treated with palliative assumption Exclusion Criteria: * Parallel patient's participation in any other clinical trial at the time when the decision over the advanced breast cancer treatment was made or up to 30 days before it.
References
Publications (1)
- DERIVEDRadecka B, Zurawski B, Lacko A, Grela-Wojewoda AA, Wieruszewska-Kowalczyk K, Senkus-Konefka E. Real-world treatment patterns of hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer. Contemp Oncol (Pozn). 2025;29(4):370-376. doi: 10.5114/wo.2025.156076. Epub 2025 Nov 11. PMID 41438813